THTaylor A. Holroyd

Taylor A. Holroyd

*This is an algorithmically generated author record based on publicly available information.

Taylor A. Holroyd has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Approximating vaccine delivery costs to reach zero-dose children: a Bayesian meta-regression analysis

    by Allison Portnoy, Emma Clarke-Deelder, Taylor A Holroyd, Daniel R Hogan, Tewodaj Mengistu

    The Immunization Agenda 2030 calls for reaching all people with immunization services, including ‘zero-dose’ children—children who have not received any routine vaccines. To plan and finance efforts to fully vaccinate these children and improve coverage and equity, decision-makers need reliable cost estimates. However, primary data on the costs of reaching zero-dose children, typically part of disadvantaged and hard-to-reach populations, are scarce. This study approximates these costs using standardized, country-level estimates of vaccine delivery unit costs for outreach delivery in low- and middle-income countries (LMICs). We extracted outreach delivery cost-per-dose estimates for childhood immunization services from the 2024 update of the Immunization Delivery Cost Catalogue. Using these data, we developed a meta-regression model to estimate standardized outreach vaccine delivery unit costs. The generalized linear model assumed a Gamma-distributed outcome with a log link and included both country-level and study-level predictors: study year, economic or financial cost basis, routine or campaign delivery, and full or incremental costing approach. The fitted model was used to estimate 2024 outreach delivery costs per dose for 129 LMICs. The model was estimated using 48 observations from 19 countries focused on outreach or mobile vaccine delivery. The best-fitting specification included diphtheria-tetanus-pertussis (DTP1) coverage, per-capita gross domestic product, and under-five population size as predictors. For 2024, the predicted mean economic cost per dose was $8.65 (95% credible interval $2.33–23.71), averaged across all 129 LMICs. To fully immunize a zero-dose child with 13 recommended vaccinations, the equivalent cost estimate was $112.45 ($30.29–308.23). Reaching zero-dose children is crucial for improving equity in global health, and estimates of the costs of doing so are needed to inform budgeting for immunization programs. These meta-regression-based cost estimates can help countries to improve budgeting, planning, and resource allocation for efforts to reach zero-dose children.


  • Open Access

    Standardized country-level delivery unit cost estimates for routine childhood, routine adolescent, and campaign vaccination: an updated modeling analysis

    by Allison Portnoy, Emma Clarke-Deelder, Taylor A. Holroyd, Daniel R. Hogan, Alex Olateju Adjagba, Logan Brenzel, Bryan N. Patenaude, So Yoon Sim, Tewodaj Mengistu, Nicolas A. Menzies

    Background: Reliable estimates of immunization delivery costs are essential for planning, budgeting, and economic evaluation. Despite recent empirical studies, many low- and middle-income countries (LMICs) lack up-to-date cost estimates, particularly for adolescent and campaign vaccination. This study generated standardized country-level delivery cost estimates across vaccination modalities in LMICs. Methods: Using data from empirical costing studies in the 2024 update of the Immunization Delivery Cost Catalogue, we fitted Bayesian meta-regression models to estimate per-dose delivery costs, not including vaccine and injection supplies costs, for routine childhood vaccination, routine adolescent vaccination (using human papillomavirus vaccination as a proxy), and mass campaigns. Models incorporated country-level covariates (gross domestic product per capita, population size, diphtheria-tetanus-pertussis third-dose coverage, urbanization, population density, and under-five mortality) and study-level characteristics (cost category and costing perspective). Fitted models were used to generate country-specific and population-weighted mean economic and financial costs per dose in 2024 US dollars. Results: The analysis included 141 observations for routine childhood, 49 for adolescent, and 104 for campaign vaccination. The population-weighted mean full economic cost per dose across LMICs was $4.27 (95% prediction interval: $1.95–11.58) for routine childhood vaccination, $20.56 ($8.56–57.83) for adolescent vaccination, and $14.71 ($4.90–86.98) for campaigns. Corresponding estimates for incremental economic costs per dose were $16.64 ($7.90–38.22), $20.43 ($8.27–47.78), and $3.53 ($1.70–8.56). Substantial heterogeneity was observed across countries, delivery modalities, and cost perspectives. Conclusions: Leveraging an expanded evidence-base and Bayesian meta-regression, this study provides updated delivery cost estimates across vaccination modalities for 136 LMICs. These estimates offer a practical resource for analyses where empirical cost data are unavailable. Key points: This study provides updated estimates of how much it costs to deliver vaccines across low- and middle-income countries, showing that costs vary widely depending on how vaccines are delivered and the context of each country. On average, delivering vaccines to adolescents (facility-based, school-based, and outreach) is substantially more expensive than routine childhood vaccination, while campaign delivery costs fall in between, reflecting differences in logistics and delivery strategies. These results offer practical, comparable cost benchmarks that policymakers and researchers can use to plan immunization programs and make informed decisions when country-specific data are not available.


  • Open Access

    Approximating vaccine delivery costs to reach zero-dose children: a Bayesian meta-regression analysis

    by Allison Portnoy, Emma Clarke-Deelder, Taylor A. Holroyd, Daniel R. Hogan, Tewodaj Mengistu

    Introduction The Immunization Agenda 2030 calls for reaching all people with immunization services, including ‘zero-dose’ children—children who have not received any routine vaccines. To plan and finance efforts to fully vaccinate these children and improve coverage and equity, decision-makers need reliable cost estimates. However, primary data on the costs of reaching zero-dose children, typically part of disadvantaged and hard-to-reach populations, are scarce. This study approximates these costs using standardized, country-level estimates of vaccine delivery unit costs for outreach delivery in low- and middle-income countries (LMICs). Methods We extracted outreach delivery cost-per-dose estimates for childhood immunization services from the 2024 update of the Immunization Delivery Cost Catalogue. Using these data, we developed a meta-regression model to estimate standardized outreach vaccine delivery unit costs. The generalized linear model assumed a Gamma-distributed outcome with a log link and included both country-level and study-level predictors: study year, economic or financial cost basis, routine or campaign delivery, and full or incremental costing approach. The fitted model was used to estimate 2024 outreach delivery costs per dose for 129 LMICs. Results The model was estimated using 48 observations from 19 countries focused on outreach or mobile vaccine delivery. The best-fitting specification included diphtheria-tetanus-pertussis (DTP1) coverage, per-capita gross domestic product, and under-five population size as predictors. For 2024, the predicted mean economic cost per dose was $8.65 (95% uncertainty interval $2.33–23.71), averaged across all 129 LMICs. To fully immunize a zero-dose child with 13 recommended vaccinations, the equivalent cost estimate was $112.45 ($30.29–308.23). Conclusion Reaching zero-dose children is crucial for improving equity in global health, and estimates of the costs of doing so are needed to inform budgeting for immunization programs. These meta-regression-based cost estimates can help countries to improve budgeting, planning, and resource allocation for efforts to reach zero-dose children. What is already known on this topic ∘ Despite global commitments under the Immunization Agenda 2030, millions of “zero-dose” children in low- and middle-income countries (LMICs) remain unvaccinated, often due to poverty, geographic inaccessibility, or conflict. ∘ Few studies have directly quantified the costs of reaching zero-dose children; existing evidence is fragmented and limited to small-scale or country-specific interventions. What this study adds ∘ Using a Bayesian meta-regression framework, this study estimates standardized, country-level estimates of vaccine delivery costs based on data for outreach delivery—a proxy for the costs of reaching zero-dose children. ∘ The analysis estimates an average 2024 economic cost of $8.65 per dose and $112.45 per fully vaccinated zero-dose child across 129 LMICs. How this study might affect research, practice or policy ∘ This study provides an evidence base to estimate the investments needed to close immunization coverage gaps under the Immunization Agenda 2030.


  • Diagnostic accuracy of dried blood spots for serology of vaccine-preventable diseases: a systematic review

    by Taylor A. Holroyd, Francesca Schiaffino, Rachel H. Chang, Jane W. Wanyiri, Ian J. Saldanha, Margaret Gross, William J. Moss, Kyla Hayford

    Venous serum and plasma are optimal specimens for serological testing but may be logistically infeasible. Dried blood spots (DBS) are a feasible alternative, provided results are adequately sensiti...


  • Designing a Pro-Equity HPV Vaccine Delivery Program for Girls Who Have Dropped Out of School: Community Perspectives From Uttar Pradesh, India

    by Taylor A. Holroyd, Shirley D. Yan, Vineet Srivastava, Ashish Srivastava, Brian Wahl, Christopher Morgan, Somesh Kumar, Amit K. Yadav, Mary Carol Jennings

    India experiences a substantial burden of cervical cancer and accounts for nearly one third of cervical cancer deaths worldwide. While human papillomavirus (HPV) vaccines have been introduced subnationally in some states, HPV has not yet been rolled out nationally. Given the target age group, schools are the most common delivery channel for HPV vaccines, but this fails to account for local girls who never attended or no longer attend school. We conducted a qualitative, design-informed, community-based study conducted in Uttar Pradesh, India. We assessed facilitators and barriers among out-of-school girls and proposed program characteristics to inform the design of pro-equity HPV vaccine delivery programs for out-of-school girls. Programs should improve parental knowledge of the risk of cervical cancer, engage vaccinated girls as vaccine champions, utilize varied media options for low-literacy populations, and ensure that HPV vaccine services are accessible and flexible to accommodate out-of-school girls. In areas with poor or irregular school attendance among adolescent girls, HPV vaccine coverage will remain suboptimal until programs can effectively address their needs and reach this priority population. Our findings present a meaningful opportunity for program planners to purposefully design HPV vaccination programs according to these parameters, rather than modifying existing programs to include HPV vaccine. Adolescent girls, their parents, and other community members should be involved in program design to ensure that the program can effectively meet the needs of adolescent girls who are not in school.


  • Social media strategies to affect vaccine acceptance: a systematic literature review

    by Rupali J. Limaye, Taylor A. Holroyd, Madeleine Blunt, Alexandra F. Jamison, Molly Sauer, Rose Weeks, Brian Wahl, Kaitlin Christenson, Cathy Smith, Jamie Minchin, et al.

    Introduction: Vaccine hesitancy, defined as a delay in the acceptance or the refusal of vaccines despite their availability, is a growing global threat. More individuals are turning to social media for health information, including vaccine information. As such, there is an opportunity to leverage online platforms as a means to disseminate and persuade individuals toward vaccine acceptance. We sought to review literature focused on the influence of exposure to social media content on vaccine acceptance or hesitancy. Areas covered: This review focused on social networking sites (e.g. Facebook) and content communities (e.g. YouTube), to understand how exposure to vaccine information affected vaccine knowledge, attitudes, and intentions/behaviors. We searched PubMed, CINAHL, Scopus, and Inspec. We included English-language materials published from 2004 to 2020 and included interventional studies, observational studies, and impacts of policies. We excluded systematic reviews, protocols, editorials, letters, case reports, case studies, commentaries, opinion pieces, narrative reviews, and clinical guidelines. Expert opinion: Social media interventions to affect vaccine acceptance is a new but growing area of study. How a communication message is framed, who delivers the message, and network structure are critical for affecting the vaccine decision-making process. Social media should be leveraged to impact vaccine uptake.


  • Vaccinomics: a cross-sectional survey of public values

    by Jennifer E. Gerber, Janesse Brewer, Rupali J. Limaye, Andrea Sutherland, Madeleine Blunt, Taylor A. Holroyd, Gail Geller, Bruce Carleton, Jeffery Kahn, Daniel A. Salmon

    Objective: We characterize public values regarding vaccinomics, which aims to improve vaccine safety and effectiveness using genomics. Methods: Panel survey (2020) of ≥18-year-olds with embedded animation introduced vaccinomics. Sociodemographic, health, and vaccination-related items were adapted from validated scales. Novel items measured trust in public health authorities, vaccinomics-related values, and preferences for federal funding: vaccinomics compared with vaccine issues and chronic diseases. Beginning and end of survey confidence in vaccine safety was measured to assess potential changes. Data were weighted to the U.S. Census. Vaccinomics-related concerns were stratified by sociodemographic characteristics, vaccine hesitancy status (composite outcome), reported serious vaccine reactions, and trust in public health authorities (PHA). Log binomial regression models estimated associations between these variables and agency to make vaccine-related decisions. Results: Most (70.7%, N = 1,925) respondents expected vaccinomics would increase their vaccine confidence compared to now. Agreement was highest among those without serious vaccine reaction experience (unexperienced: 74.2% versus experienced: 62.3%), with high trust in PHA (high: 83.3% versus low: 57.4%), and low vaccine hesitancy among parents of teenagers (low: 78.8% versus high: 62.5%) and adults without minor children (low: 79.8% versus high: 60.6%; all p < .01). Belief that vaccination was an individual’s choice was associated with reported serious reactions (adjusted Prevalence Ratio (aPR): 1.16; 95% CI: 1.07, 1.25) and low trust (aPR: 0.91; 0.84, 0.98). Beginning versus end of survey vaccine safety perceptions were similar. Conclusion: Federal funding, communications, and policies should assure the public that vaccinomics will not remove their decision–making power and engender trust in PHA.


  • Development of a Scale to Measure Trust in Public Health Authorities: Prevalence of Trust and Association with Vaccination

    by Taylor A. Holroyd, Rupali J. Limaye, Jennifer E. Gerber, Rajiv N. Rimal, Rashelle J. Musci, Janesse Brewer, Andrea Sutherland, Madeleine Blunt, Gail Geller, Daniel A. Salmon

    Infectious disease outbreaks highlight the importance of trust in public health authorities to avoid fear and improve adherence to recommendations. There is currently no established and validated measure for trust in public health authorities. We aimed to develop and validate an instrument that measures trust in public health authorities and to assess the association between trust in public health authorities and vaccine attitudes. We developed 20 items to measure trust in public health authorities. After implementing a survey in January 2020, we investigated relationships between the items, reduced the number of items, and identified latent constructs of the scale. We assessed variability in trust and how trust was associated with vaccine attitudes, beliefs, and self-reported vaccine acceptance. The pool was reduced to a 14-item trust in public health authorities scale and we found that this trust model was strongly associated with acceptance of vaccines. Our scale can be used to examine the relationship between trust in public health authorities and adherence to public health recommendations. The measure needs to be validated in other settings to determine whether they are associated with other areas where the public question public health authority recommendations.


  • School-level perceptions and enforcement of the elimination of nonmedical exemptions to vaccination in California

    by Taylor A. Holroyd, Amanda C. Howa, Tina M. Proveaux, Paul L. Delamater, Nicola P. Klein, Alison M. Buttenheim, Rupali J. Limaye, Saad B. Omer, Daniel A. Salmon

    In 2015, California passed Senate Bill 277 eliminating all nonmedical exemptions to school vaccinations. We aimed to explore school-level modes of SB277 enforcement, characterize vaccination knowledge, attitudes, and beliefs of school officials, and identify whether school vaccination policies are associated with medical exemptions being granted. Surveys were mailed to a stratified random sample of 1,450 schools in California. School personnel (n = 752) reported their medical training, vaccination beliefs, enforcement of vaccination policies, and school rates of medical exemptions. Multiple logistic regression was used to assess whether school policies are associated with the likelihood of medical exemption requests being granted. Nurses were more likely than non-nurses to hold beliefs recognizing the importance of vaccination. A school where the survey respondent was a nurse was more likely to have granted a medical exemption request compared to a school where the respondent was not a nurse (OR 2.11, 95% CI 1.34–3.36). The training of school officials and school-level practices may impact the enforcement of medical exemptions. Equipping school officials as competent sources of vaccine information for concerned parents will be valuable in improving parental vaccine uptake.


  • Parental vaccine attitudes, beliefs, and practices: initial evidence in California after a vaccine policy change

    by Taylor A. Holroyd, Amanda C. Howa, Paul L. Delamater, Nicola P. Klein, Alison M. Buttenheim, Rupali J. Limaye, Tina M. Proveaux, Saad B. Omer, Daniel A. Salmon

    Senate Bill 277 (SB277) eliminated nonmedical exemptions for school-entry vaccines in California, but the impact of parental vaccine knowledge, attitudes, and beliefs on vaccine decision-making has not been extensively examined within the post-SB277 context. This study generates preliminary understanding and discussion of the vaccination knowledge, attitudes, and beliefs among a pilot population of parents of kindergarten students in California after the implementation of SB277. School officials administered a cross-sectional survey to parents of kindergarten children in California from April to July 2019. Parents reported their perceptions of diseases and vaccines, key immunization beliefs, and confidence in different sources of vaccine information. Most parents (92%) had fully vaccinated their children post-SB277 and generally perceived vaccines to be safe and effective, but about 44% reported they were hesitant about childhood vaccines. The majority of parents (87%) rated vaccine information from their doctor as highly credible. This pilot group of kindergarten parents was generally supportive of vaccination and had fully vaccinated their children, but most parents still harbored concerns and misconceptions about vaccines and about public health authorities. This indicates a disconnect between parental vaccine compliance and confidence, and suggests that educational interventions could impact parental vaccine behavior and decision-making.